X0306 4 2020-06-05 0 0001746473 PLIANT THERAPEUTICS, INC. PLRX 0001809204 Cummings Keith Lamont C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Financial Officer Common Stock 2020-04-30 4 M 0 19300 2.08 A 19300 D Common Stock 2020-06-05 4 C 0 3821 A 23121 D Series C Preferred Stock 2020-02-28 4 A 0 27322 13.0845 A Common Stock 3821 27322 D Stock Option (right to buy) 6.22 2020-03-31 4 A 0 42841 0.00 A 2030-03-30 Common Stock 42841 42841 D Stock Option (right to buy) 2.08 2020-04-30 4 M 0 19300 0.00 D 2029-01-23 Common Stock 19300 206188 D Series C Preferred Stock 2020-06-05 4 C 0 27322 0.00 D Common Stock 3821 0 D On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. /s/ Anthony Franks, attorney-in-fact 2020-06-09